Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) Overview
  3. Therapeutics Development
  4. Pipeline Products for Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Overview
  5. Pipeline Products for Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Comparative Analysis
  6. Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Therapeutics under Development by Companies
  7. Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Therapeutics under Investigation by Universities/Institutes
  8. Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Products under Development by Companies
  13. Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Products under Investigation by Universities/Institutes
  14. Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Companies Involved in Therapeutics Development
  • FibroGen, Inc.
  • RXi Pharmaceuticals Corporation

For more information visit http://www.researchandmarkets.com/research/kjcx2s/connective_tissue

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs